GLP-1s under $200 a month: the shortlist

A provider lands on this list when its semaglutide or tirzepatide costs less than $200 for a calendar month at the standing price. That's the rate you'd keep paying, not a first-month promo and not a figure that needs a year paid up front.

Plans that bill every four weeks are converted first. Four-week billing means a fixed 28-day charge interval, so a plan printed at a round number per supply works out a little higher per month. Confirm the billing clause rather than inferring the charge interval from a stated medication supply.

Every product that clears the line is compounded. The brand pens don't get under $200 at their standing self-pay prices: Novo Nordisk lists Wegovy pens at $349 a month, and Lilly lists Zepbound at $299 for the starting dose.

GLP-1 doses go up over the first months, and some prices go up with them. A figure under $200 can be the price of the first dose only, so the question that matters is what you'll pay once your prescriber has raised it.

A flat-dose claim is only one part of the agreement. Check whether the quoted price covers your selected dose, formulation, required membership and actual charge interval. A medication supply described as four weeks does not prove a four-week charge. Programs with unresolved recurring totals do not receive an assumed low-price position here.

The brands show how much a dose ladder can add. Lilly prices Zepbound at $299 for the starting dose, $399 for the next and $449 for the higher doses when you refill within 45 days, or up to $699 if you don't. Wegovy pens stay at $349 across the standard doses.

Three prices often sit on one page. An intro rate covers the first month. The standing rate is what renews. A prepaid rate is lower per month but charged as one big total.

HealthRX publishes introductory, continuing and longer-plan offers. Ask which applies to your selected prescription and whether the advertised first supply changes the renewal total. The comparison uses a supported standing quote, not an opening promotion or a prepaid figure presented as a cancellable monthly plan.

Prepaying commits more cash before your response is known. Longer-plan savings may exclude already prescribed medication from refunds, even when future care can be stopped. Read the selected agreement, including early processing and cancellation cutoffs. A low monthly equivalent is not the amount charged today.

A low number means more when it covers the same things. Some offers include clinical review, medication and shipping; others separate these charges. Read the provider review and selected treatment agreement rather than applying an inclusion statement from one product to the whole catalog.

Labs are where bills split. BioGlow Health builds its plans on your lab results, and a couple of picks here charge a separate lab fee. Ask whether bloodwork is in the price, billed apart or left to your own doctor.

Also check for a membership on top. A plan with no membership fee and a plan that needs one can print the same medication price and cost you different amounts.

The filter examines the exact matching product and its verified recurring total. Injection and needle-free offers can have different eligibility, dose pricing and billing commitments. Do not assume an advertised oral offer qualifies simply because its starting price is below the limit. Unresolved prices cannot establish that a program stays under the budget.

None of those forms is an FDA-approved product. Compounded drops and tablets weren't part of the trials behind the brand drugs, so ask the prescriber how they expect the form to compare with a shot.

Compounded preparations are pharmacy-made products whose formulation, quality and absorption must be assessed separately from approved brands. They aren't FDA-approved, and FDA doesn't review them for safety, effectiveness or quality before they're dispensed.

The room for compounding has narrowed. FDA declared the tirzepatide shortage over on December 19, 2024 and the semaglutide shortage over on February 21, 2025, and pharmacies may no longer make routine copies of the brands. On April 30, 2026, FDA also proposed keeping both off the list of bulk ingredients that outsourcing facilities may use. The semaglutide and tirzepatide explainers track where that stands.

That's the practical reason to think twice before paying a year up front. If the rules change mid-plan, ask now what happens to a prepaid balance.

What will month three cost at the dose I expect? Get the figure in writing, not the starting-dose price.

Is it billed monthly or every four weeks? A fixed 28-day charge has a different annualized cost from a calendar-month charge; actual cash dates depend on when the plan starts.

What's left out? Labs, a visit fee, a membership or supplies can each sit outside the plan price.

What are the refund terms on a prepaid plan? Read them before you choose the longer plan. If a GLP-1 isn't settled for you yet, start with the full metabolic list or take the quiz.